FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623157416> ?p ?o ?g. }

• W2623157416 endingPage "e27" @default.
• W2623157416 startingPage "e15" @default.
• W2623157416 abstract "Objectives The American Pharmacists Association (APhA) convened the Biologics and Biosimilars Stakeholder Conference on November 30, 2016, in Washington DC. The objectives of the Conference were to determine the key issues and challenges within the marketplace for biologics, follow-on biologics (FOBs), and biosimilars, identify potential roles and responsibilities of pharmacists regarding biologic and biosimilar medications, and identify actions or activities that pharmacists may take to optimize the safe and cost-effective use of biologics and biosimilars. Data sources National thought leaders and stakeholder representatives, including individuals from the Food and Drug Administration, Centers for Medicare and Medicaid Services, a private third-party payer, manufacturers, and several national organizations of health care professionals, participated in the conference. Information shared by this group was supplemented with relevant legal and regulatory information and published literature. Summary Biologics play a valuable role in the treatment of numerous health conditions, but their associated costs, which tend to be greater than those of small-molecule drugs, place a burden on the health care system. Biosimilars (both noninterchangeable and interchangeable) are highly similar copies of the originator biologic and offer the potential to reduce costs and improve patient access to biological products by increasing treatment options and creating a more competitive market. Despite the potential benefits of biosimilars, certain factors may limit their uptake. The conference participants explored issues that different stakeholders think influence the use of biologics, including biosimilars, in the United States. Barriers included technology, prescriber–pharmacist communication, legislation and regulations, limited patient and health care practitioner knowledge of biological products, patient and health care practitioner perceptions of biosimilars, and evolving science or lack of long-term data. After participants identified issues, they discussed strategies to address these concerns, including the need to enhance the education of pharmacists, prescribers, and patients regarding biologic products, including biosimilars and FOBs; the passage of state laws and regulations that do not impede the use of biosimilars, including interchangeable biosimilars; the use of product-specific tracking information in electronic health records and surveillance systems; bidirectional communication among pharmacists, prescribers, and other members of the care team to support pharmacovigilance and the maintenance of accurate patient records; and the development of evidence-based third-party payer policies. Conclusion Patient access to safe and cost-effective treatments is an important goal for the health care system. As the availability and use of biosimilars, including those determined to be interchangeable, increases, their potential to lower costs and improve patient access to treatment grows. However, the extent of such growth is, in part, dependent on various stakeholders’ decisions to provide, pay for, or use these products in a safe and thoughtful manner. Ongoing stakeholder collaboration, educational activities, and review of current government or payer policies are required to optimize the uptake of biological products, including biosimilars." @default.
• W2623157416 created "2017-06-15" @default.
• W2623157416 creator A5051856971 @default.
• W2623157416 creator A5055343057 @default.
• W2623157416 date "2017-09-01" @default.
• W2623157416 modified "2023-09-29" @default.
• W2623157416 title "The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference" @default.
• W2623157416 cites W2005681010 @default.
• W2623157416 cites W2056762024 @default.
• W2623157416 cites W2060227370 @default.
• W2623157416 cites W2080611602 @default.
• W2623157416 cites W2089190513 @default.
• W2623157416 cites W2142289247 @default.
• W2623157416 cites W2151188170 @default.
• W2623157416 cites W2180859504 @default.
• W2623157416 cites W2545293585 @default.
• W2623157416 doi "https://doi.org/10.1016/j.japh.2017.05.014" @default.
• W2623157416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28689708" @default.
• W2623157416 hasPublicationYear "2017" @default.
• W2623157416 type Work @default.
• W2623157416 sameAs 2623157416 @default.
• W2623157416 citedByCount "22" @default.
• W2623157416 countsByYear W26231574162018 @default.
• W2623157416 countsByYear W26231574162019 @default.
• W2623157416 countsByYear W26231574162020 @default.
• W2623157416 countsByYear W26231574162021 @default.
• W2623157416 countsByYear W26231574162022 @default.
• W2623157416 countsByYear W26231574162023 @default.
• W2623157416 crossrefType "journal-article" @default.
• W2623157416 hasAuthorship W2623157416A5051856971 @default.
• W2623157416 hasAuthorship W2623157416A5055343057 @default.
• W2623157416 hasConcept C126322002 @default.
• W2623157416 hasConcept C160735492 @default.
• W2623157416 hasConcept C162324750 @default.
• W2623157416 hasConcept C17744445 @default.
• W2623157416 hasConcept C199539241 @default.
• W2623157416 hasConcept C201305675 @default.
• W2623157416 hasConcept C2776534028 @default.
• W2623157416 hasConcept C2776643233 @default.
• W2623157416 hasConcept C2777351106 @default.
• W2623157416 hasConcept C39549134 @default.
• W2623157416 hasConcept C50522688 @default.
• W2623157416 hasConcept C59491497 @default.
• W2623157416 hasConcept C71924100 @default.
• W2623157416 hasConceptScore W2623157416C126322002 @default.
• W2623157416 hasConceptScore W2623157416C160735492 @default.
• W2623157416 hasConceptScore W2623157416C162324750 @default.
• W2623157416 hasConceptScore W2623157416C17744445 @default.
• W2623157416 hasConceptScore W2623157416C199539241 @default.
• W2623157416 hasConceptScore W2623157416C201305675 @default.
• W2623157416 hasConceptScore W2623157416C2776534028 @default.
• W2623157416 hasConceptScore W2623157416C2776643233 @default.
• W2623157416 hasConceptScore W2623157416C2777351106 @default.
• W2623157416 hasConceptScore W2623157416C39549134 @default.
• W2623157416 hasConceptScore W2623157416C50522688 @default.
• W2623157416 hasConceptScore W2623157416C59491497 @default.
• W2623157416 hasConceptScore W2623157416C71924100 @default.
• W2623157416 hasIssue "5" @default.
• W2623157416 hasLocation W26231574161 @default.
• W2623157416 hasLocation W26231574162 @default.
• W2623157416 hasOpenAccess W2623157416 @default.
• W2623157416 hasPrimaryLocation W26231574161 @default.
• W2623157416 hasRelatedWork W144471065 @default.
• W2623157416 hasRelatedWork W2059444103 @default.
• W2623157416 hasRelatedWork W2156182319 @default.
• W2623157416 hasRelatedWork W2412192208 @default.
• W2623157416 hasRelatedWork W2901492289 @default.
• W2623157416 hasRelatedWork W3096200735 @default.
• W2623157416 hasRelatedWork W3158965239 @default.
• W2623157416 hasRelatedWork W4205098836 @default.
• W2623157416 hasRelatedWork W4207052112 @default.
• W2623157416 hasRelatedWork W4229808080 @default.
• W2623157416 hasVolume "57" @default.
• W2623157416 isParatext "false" @default.
• W2623157416 isRetracted "false" @default.
• W2623157416 magId "2623157416" @default.
• W2623157416 workType "article" @default.